Xanthus To Develop Lung Cancer Therapy Following Deal With Schering AG
This article was originally published in The Pink Sheet Daily
Executive Summary
Xanthus licenses the peptide PD045, which management originally developed at Diatide prior to acquisition by Schering AG.
You may also be interested in...
Xanthus Will Develop Oral Fludarabine For U.S. Market
Schering AG opts to out-license the oncologic rather than invest in further clinical study to support U.S. approval of the new dosage form.
J.P. Morgan, Without The Parties, Reveals An Industry Ready To Get Down To Business
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: